This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00098892%3A_____%2F13%3A%230000486%21RIV14-MZ0-00098892/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00098892%3A_____%2F13%3A%230000486%21RIV14-MZ0-00098892
rdf:type
skos:Concept n13:Vysledek
dcterms:description
Aims We assessed long-term outcome of consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (INF-?) in Central and Northern Moravia between 1989 and 2006. Methods A retrospective study focused on the response, prognostic factors and side effects of INF-?. Results 118 patients (67 males and 51 females at a median age 50 years; range 18-71) were analyzed. The median follow-up was 82.6 months (12.4-212.6). Thirty-six patients (30.5%) achieved major cytogenetic response (CyR) in median of 18.3 months (3.7-47.3) and maintained it for median of 64.0 months (7.0-176.0). Sixty-one patients treated with INF-? for more than 12 months had overall survival (OS) 137.0 months (95% CI 117.6-156.4). Eighteen (29.5%) of them achieved complete CyR (CCyR). 109 patients discontinued the treatment with INF-? because of hematologic or cytogenetic resistance in 53 (48.7%), progression of CML in 31 (28.4%) and intolerance to INF-? in 17 (15.6%) patients Aims We assessed long-term outcome of consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (INF-?) in Central and Northern Moravia between 1989 and 2006. Methods A retrospective study focused on the response, prognostic factors and side effects of INF-?. Results 118 patients (67 males and 51 females at a median age 50 years; range 18-71) were analyzed. The median follow-up was 82.6 months (12.4-212.6). Thirty-six patients (30.5%) achieved major cytogenetic response (CyR) in median of 18.3 months (3.7-47.3) and maintained it for median of 64.0 months (7.0-176.0). Sixty-one patients treated with INF-? for more than 12 months had overall survival (OS) 137.0 months (95% CI 117.6-156.4). Eighteen (29.5%) of them achieved complete CyR (CCyR). 109 patients discontinued the treatment with INF-? because of hematologic or cytogenetic resistance in 53 (48.7%), progression of CML in 31 (28.4%) and intolerance to INF-? in 17 (15.6%) patients
dcterms:title
Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia
skos:prefLabel
Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia
skos:notation
RIV/00098892:_____/13:#0000486!RIV14-MZ0-00098892
n13:predkladatel
n15:ico%3A00098892
n3:aktivita
n9:Z n9:S n9:I
n3:aktivity
I, S, Z(MSM6198959205), Z(MSM6198959223)
n3:cisloPeriodika
3
n3:dodaniDat
n11:2014
n3:domaciTvurceVysledku
n5:9788662 n5:3547159 n5:9589864 n5:2556049
n3:druhVysledku
n18:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
80743
n3:idVysledku
RIV/00098892:_____/13:#0000486
n3:jazykVysledku
n16:eng
n3:klicovaSlova
chronic myeloid leukemia, interferon-alpha, cytogenetic response
n3:klicoveSlovo
n12:chronic%20myeloid%20leukemia n12:interferon-alpha n12:cytogenetic%20response
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[CCA738D63EC2]
n3:nazevZdroje
Biomedical Papers-Olomouc
n3:obor
n7:FD
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n11:2013
n3:svazekPeriodika
157
n3:tvurceVysledku
Kuba, Adam Faber, Edgar Rohoň, Peter Divoká, Martina
n3:zamer
n14:MSM6198959205 n14:MSM6198959223
s:issn
1213-8118
s:numberOfPages
9